Yi Shen1*, Xu-Lin Wang1*, Jin-Ping Xie1, Jian-Guo Shao2, Yi-Hua Lu1, Sheng Zhang1, Gang Qin2
1) Department of Epidemiology and Medical Statistics, School of Public Health, Nantong University, Nantong, Jiangsu;
2) Center for Liver Diseases, Nantong Third People’s Hospital, Nantong University, Nantong, Jiangsu, China
ABSTRACT Background & Aims: The involvement of thyroid autoimmunity and dysfunction in patients with chronic
hepatitis C virus (HCV) infection before interferon-α (IFN-α) therapy remains controversial. We performed
this meta-analysis to evaluate the association of HCV infection with the presence of anti-thyroid antibodies
Methods: A literature search was carried out to collect articles dated up to August 2015 to identify observational
studies which compared the prevalence of anti-thyroid antibodies and thyroid dysfunction in IFN-α naïve
chronic HCV-infected subjects with non-HCV infected controls. Random-effect or fixed-effect meta-analyses
were applied and results reported as odds ratios (ORs) with 95% confidence intervals (CIs).
Results: Twelve studies were included, involving 1,735 HCV-infected and 1,868 non-HCV infected subjects.
Pooled anti-thyroid antibody prevalence tended to be higher in HCV-infected subjects. The prevalence of
anti-thyroglobulin antibody (TGAb), anti-thyroid peroxidase antibody (TPOAb), anti-thyroid microsomal
antibody (ATMA) were 2.40-fold, 1.96-fold and 1.86-fold higher in HCV-infected subjects than in controls,
respectively. The prevalence of hypothyroidism also differed by HCV infection status, with a pooled risk of
3.10 (95%CI: 2.19-4.40) in HCV-infected subjects. However, the results did not show a significant difference
in the prevalence of hyperthyroidism between the two groups. Conclusion: Chronic HCV infection may be an independent risk factor for thyroid disturbance. It is advisable
for the clinicians to monitor both thyroid antibodies and function in the course of chronic HCV infection,
independent of IFN-α treatment.